-
公开(公告)号：US09394234B2
公开(公告)日：2016-07-19
申请号：US14319996
申请日：2014-06-30
发明人： Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号： C07C227/00 , C07B43/00 , C07C227/18 , A61K9/127 , A61K31/22 , A61K31/7088 , A61K38/17 , A61K38/48 , C07C229/12 , C07D475/04 , C12N15/113 , A61K47/48 , A61K48/00 , A61K47/14 , C07C29/58 , C07C227/40
CPC分类号： A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要： The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译： 本发明的特征在于式I的阳离子脂质，包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号：US20160024498A1
公开(公告)日：2016-01-28
申请号：US14700938
申请日：2015-04-30
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/567 , A61K9/127 , A61K31/366
CPC分类号： C12N15/113 , A61K9/127 , A61K31/366 , A61K31/567 , A61K31/7088 , C12N9/6454 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12N2320/31 , C12N2320/32 , C12Y304/21061
摘要： This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
摘要翻译： 本发明涉及通过预先施用降低LDL受体水平的试剂来提高siRNA施用效率的方法。
-
公开(公告)号：US20160213785A1
公开(公告)日：2016-07-28
申请号：US14953677
申请日：2015-11-30
发明人： Muthiah Manoharan , Kallanthottathil G. Rajeev , David Butler , Jayaprakash K. Narayanannair , Muthusamy Jayaraman , Laxman Eltepu
IPC分类号： A61K47/44 , C07D317/44 , C07D317/46 , A61K31/713 , C07D317/28 , C07D491/113 , C07D317/72 , A61K31/7088 , C07D491/056 , C07D405/12
CPC分类号： A61K47/44 , A61K9/1272 , A61K31/7088 , A61K31/713 , A61K39/00 , A61K39/39 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/28 , A61K2039/55555 , A61K2039/55561 , C07C229/08 , C07C229/30 , C07C237/16 , C07C251/38 , C07C251/78 , C07C271/12 , C07C271/20 , C07C323/25 , C07D203/10 , C07D317/28 , C07D317/44 , C07D317/46 , C07D317/72 , C07D319/06 , C07D405/12 , C07D491/056 , C07D491/113 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/3515 , C12N2320/32 , Y02A50/464
摘要： The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures:
摘要翻译： 本发明提供有利地用于脂质颗粒以用于体内递送治疗剂至细胞的脂质。 特别地，本发明提供具有以下结构的脂质：
-
公开(公告)号：US20160199485A1
公开(公告)日：2016-07-14
申请号：US14884489
申请日：2015-10-15
发明人： Muthiah Manoharan , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , Laxman Eltepu , Steven Ansell , Jianxin Chen
IPC分类号： A61K39/39 , A61K31/713 , C12N15/113 , C07D317/28 , C07D203/10 , C07C229/30 , C07C229/08 , C07D319/06
CPC分类号： A61K47/44 , A61K9/1272 , A61K31/7088 , A61K31/713 , A61K39/00 , A61K39/39 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/28 , A61K2039/55555 , A61K2039/55561 , C07C229/08 , C07C229/30 , C07C237/16 , C07C251/38 , C07C251/78 , C07C271/12 , C07C271/20 , C07C323/25 , C07D203/10 , C07D317/28 , C07D317/44 , C07D317/46 , C07D317/72 , C07D319/06 , C07D405/12 , C07D491/056 , C07D491/113 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/3515 , C12N2320/32 , Y02A50/464
摘要： The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40 K), optionally substituted mPEG (mw 120-40 K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).
摘要翻译： 本发明提供有利地用于脂质颗粒以用于体内递送治疗剂至细胞的脂质。 特别地，本发明提供了具有以下结构的脂质，其中：R1和R2各自独立地为每次出现任选取代的C 10 -C 30烷基，任选取代的C 10 -C 30烯基，任选取代的C 10 -C 30炔基，任选取代的C 10 -C 30酰基， 或 - 连接子 - 配体; R 3为H，任选取代的C 1 -C 10烷基，任选取代的C 2 -C 10烯基，任选取代的C 2 -C 10炔基，烷基硫代烷基磷酸酯，烷基硫代磷酸酯，烷基二硫代磷酸酯，烷基膦酸酯，烷基胺，羟基烷基，ω-氨基烷基，ω-（取代的）氨基烷基， ω-磷酸烷基酯，ω-硫代磷酰基烷基酯，任选取代的聚乙二醇（PEG，mw 100-40K），任选取代的mPEG（mw 120-40K），杂芳基，杂环或连接体 - 配体; 并且E是C（O）O或OC（O）。
-
公开(公告)号：US20150265708A1
公开(公告)日：2015-09-24
申请号：US14629991
申请日：2015-02-24
发明人： Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Jayaprakash K. Narayanannair , Martin Maier , Laxman Eltepu
IPC分类号： A61K47/18 , C07C271/20 , C07C323/25 , A61K47/10 , C07C251/38 , C07C271/12 , A61K47/20 , A61K47/28 , C07C251/78 , C07C237/16
CPC分类号： A61K47/44 , A61K9/1272 , A61K31/7088 , A61K31/713 , A61K39/00 , A61K39/39 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/28 , A61K2039/55555 , A61K2039/55561 , C07C229/08 , C07C229/30 , C07C237/16 , C07C251/38 , C07C251/78 , C07C271/12 , C07C271/20 , C07C323/25 , C07D203/10 , C07D317/28 , C07D317/44 , C07D317/46 , C07D317/72 , C07D319/06 , C07D405/12 , C07D491/056 , C07D491/113 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/3515 , C12N2320/32 , Y02A50/464
摘要： The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.
摘要翻译： 本发明提供有利地用于脂质颗粒以用于体内递送治疗剂至细胞的脂质。 特别地，本发明提供具有以下结构的脂质，其中每个出现的R 1和R 2各自独立地为任选取代的C 10 -C 30烷基，任选取代的C 10 -C 30烯基，任选取代的C 10 -C 30炔基，任选取代的C 10 -C 30酰基或 连接子 - 配体; R 3为H，任选取代的C 1 -C 10烷基，任选取代的C 2 -C 10烯基，任选取代的C 2 -C 10炔基，烷基硫代烷基磷酸酯，烷基硫代磷酸酯，烷基二硫代磷酸酯，烷基膦酸酯，烷基胺，羟基烷基，ω-氨基烷基，ω-（取代的）氨基烷基， ω-磷酸烷基酯，ω-硫代磷酰基烷基酯，任选取代的聚乙二醇（PEG，mw 100-40K），任选取代的mPEG（mw 120-40K），杂芳基，杂环或连接基 - 配体; E是O，S，N（Q），C（O），N（Q）C（O），C（O）N（Q），（Q） ），S（O），NS（O）2N（Q），S（O）2，N（Q）S（O）2，SS，O = N，芳基，杂芳基，环状或杂环; Q为H，烷基，ω-氨基烷基，ω-（取代）氨基烷基，ω-磷酸烷基或ω-硫代磷酰基烷基。
-
公开(公告)号：US20150190515A1
公开(公告)日：2015-07-09
申请号：US14508805
申请日：2014-10-07
发明人： Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Michael E. Jung
IPC分类号： A61K47/22 , C12N15/113 , C07D295/13
CPC分类号： A61K47/22 , A61K9/1272 , C07D295/13 , C12N15/113 , C12N15/1137 , C12N2310/14 , Y02A50/463
摘要： Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).
摘要翻译： 本文公开了包含式（I）的阳离子脂质，中性脂质，固醇和PEG或PEG修饰的脂质的脂质组合物，其中式（I）还公开了制备式（I）的阳离子脂质的方法， 。
-
公开(公告)号：US20150166465A1
公开(公告)日：2015-06-18
申请号：US14319996
申请日：2014-06-30
发明人： Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号： C07C227/18 , C07C29/58 , C07C227/40
CPC分类号： A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要： The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译： 本发明的特征在于式I的阳离子脂质，包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号：US20140179761A1
公开(公告)日：2014-06-26
申请号：US14060353
申请日：2013-10-22
发明人： Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号： A61K47/28 , A61K31/713 , A61K31/7088 , A61K47/16 , A61K47/22
CPC分类号： A61K47/28 , A61K31/70 , A61K31/7004 , A61K31/7052 , A61K31/7088 , A61K31/713 , A61K47/16 , A61K47/22 , A61K47/543 , A61K47/549 , A61K47/60 , A61K48/00 , C07H21/02 , Y02A50/385 , Y02A50/411 , Y02A50/467 , Y02P20/55
摘要： The present invention provides targeting lipids of structure L100-linker-L101 (CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
摘要翻译： 本发明提供结构L100-接头-L101（CI）的靶向脂质，其中L100是脂质，亲脂性，烷基，烯基或炔基，L101是配体或-CH2CH2（OCH2CH2）pO（CH2）qCH2-配体，p 为1-1000，q为1-20。 此外，本发明提供了将治疗剂递送至细胞的组合物和方法。 特别地，这些包括提供核酸的有效包封的新型脂质和核酸 - 脂质颗粒，并将包封的核酸有效地递送到细胞体内。
-
公开(公告)号：US09801874B2
公开(公告)日：2017-10-31
申请号：US14646359
申请日：2013-11-20
IPC分类号： A61K31/475 , A61K9/127
CPC分类号： A61K31/475 , A61K9/127 , A61K9/1272 , A61K9/1278
摘要： Improved methods for efficiently constituting liposome encapsulated vincristine for intravenous injection (VSLI) with reduced risk of operational errors and contamination are disclosed.
-
公开(公告)号：US20160317676A1
公开(公告)日：2016-11-03
申请号：US15152216
申请日：2016-05-11
申请人： Tekmira Pharmaceuticals Corporation , The University of British Columbia , Acuitas Therapeutics Inc.
发明人： Michael J. Hope , Thomas D. Madden , Pieter R. Cullis , Martin Maier , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , Akin Akinc , Muthiah Manoharan , Ismail Hafez
CPC分类号： A61K47/543 , A61K9/1272 , A61K47/6911 , C12N15/88
摘要： A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.032 秒)
